INmune Bio Reports 2025 Progress and Outlines 2026 Initiatives for CORDStrom and XPro Programs
ByAinvest
Tuesday, Jan 27, 2026 9:27 am ET1min read
INMB--
INmune Bio's 2025 milestones include progress in its Phase 2 Alzheimer's disease trial with XPro™ and significant advancements in its CORDStrom™ program for recessive dystrophic epidermolysis bullosa (RDEB). The company plans to submit a Marketing Authorization Application (MAA) to the UK's MHRA and a Biologics License Application (BLA) to the US FDA in 2026. The focus remains on harnessing the innate immune system to address conditions with large unmet needs and significant market potential.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet